BRIEF-Astrazeneca Says Eplontersen Ph III Trial Met Co-Primary Endpoints

AstraZeneca PLC: * ASTRAZENECA PLC - EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS

* ASTRAZENECA - NEW DRUG APPLICATION FILING ANTICIPATED BASED ON POSITIVE DATA FROM INTERIM ANALYSIS * ASTRAZENECA - HIGH-LEVEL RESULTS SHOWED TRIAL ALSO MET ITS SECONDARY ENDPOINT

* ASTRAZENECA - ATTRV-PN IS EXPECTED TO BE FIRST INDICATION FOR WHICH ASTRAZENECA AND IONIS WILL SEEK REGULATORY APPROVAL FOR EPLONTERSEN Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)